Antimicrobial Resistance
Bacterial antimicrobial resistance directly caused an estimated 1.27 million deaths in 2019 and was associated with 4.95 million more — placing AMR among the top global causes of mortality, ahead of HIV and malaria combined. The Lancet projects 1.91 million directly attributable deaths a year by 2050 on current trends.
Key insights
AMR mortality already at HIV+TB levels
The 2022 Lancet GRAM study put bacterial AMR among the top three causes of mortality globally. Six pathogens — E. coli, S. aureus, K. pneumoniae, S. pneumoniae, A. baumannii, P. aeruginosa — accounted for 73% of AMR deaths. Lower respiratory tract and intra-abdominal infections were the most lethal sites. Sub-Saharan Africa carries the highest age-standardised burden.
Consumption drives selection pressure
Global human antibiotic consumption rose ~46% between 2000 and 2018. Veterinary use exceeds human use in tonnes — roughly 100,000 tonnes a year globally — concentrated in intensive livestock production. The EU banned growth-promoter antibiotics in 2006; the US restricted them in 2017. China cut veterinary use by ~50% from 2015 peaks. India remains the largest single human-antibiotic consumer.
The development pipeline is thin
Only 13 new antibiotics with novel mechanisms reached approval since 2017. The economics are broken — society wants new antibiotics held in reserve, which destroys the commercial case for development. Pull incentives (UK NHS subscription model, US PASTEUR Act proposals) are emerging. Most pipeline candidates target gram-negative resistance, which is the highest WHO priority area.
Annual deaths — major causes (latest available)
Global deaths, millions
Key Finding: Bacterial AMR-associated mortality (4.95M) already exceeds HIV/AIDS, TB and malaria combined.
Human antibiotic consumption — selected countries
Defined daily doses per 1,000 inhabitants per day
Key Finding: Greece, France and Belgium lead OECD consumption; the Netherlands and Sweden run notably tight stewardship.
Methodology & caveats
Attributable vs associated deaths
GRAM distinguishes deaths directly attributable to AMR (would not have occurred with a fully susceptible pathogen) from deaths associated with AMR (occurred in someone with a resistant infection, but causal attribution is uncertain). The two estimates bracket the true burden.
Surveillance gaps
WHO's Global Antimicrobial Resistance and Use Surveillance System (GLASS) collected data from 127 countries in 2024 but coverage is patchy in low-income settings. Many AMR deaths in sub-Saharan Africa are modelled from a small number of sentinel sites; uncertainty intervals are wide.
Veterinary use limits
Total antibiotic mass used in livestock exceeds human use, but per-kilogram tissue treated the figures are comparable. The fraction of human resistance traceable to veterinary use is contested — molecular epidemiology suggests it's significant for some pathogen-drug combinations (colistin/E. coli) and minor for others. The One Health approach treats human, animal and environmental use as a single system.